Clinical Trial Update: A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 trial evaluating the safety, reactogenicity, and immune response of GSK's RSV vaccine candidate GSK3844766A in older adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• GSK3844766A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-03-23